Rephonic
Artwork for Hematologic Oncology Update

Hematologic Oncology Update

Dr. Neil Love
Myelofibrosis
Multiple Myeloma
Bispecific Antibodies
Clinical Trials
Follicular Lymphoma
Cytokine Release Syndrome
Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Acute Myeloid Leukemia
Anemia
Lymphoma
JAK Inhibitors
ASCO Meeting
CAR T-Cell Therapy
Chronic Lymphocytic Leukemia
Paroxysmal Nocturnal Hemoglobinuria
Health Disparities
Ruxolitinib
Ash Meeting
Myelodysplastic Syndromes

Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.

PublishesTwice weeklyEpisodes545Founded18 years ago
Number of ListenersCategories
ScienceHealth & FitnessMedicine

Listen to this Podcast

Artwork for Hematologic Oncology Update

Latest Episodes

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

CME information and select pub... more

YouTube

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia... more

YouTube

Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.

CME information and select publications here.

YouTube

Prof Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.

CME information and select publications here.

YouTube

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Blood Cancer Talks
Blood Cancer TalksRajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Two Onc Docs
Two Onc DocsSam and Karine
Blood Podcast
Blood PodcastAmerican Society of Hematology
WolverHeme Happy Hour
WolverHeme Happy HourBernard Marini, Anthony Perissinotti, et al.

Recent Guests

Bijal Shah
Oncologist at Moffitt Cancer Center
Moffitt Cancer Center, Tampa, FL
Episode: CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah
Constantine Tam
Professor at Monash University, Melbourne
Monash University
Episode: Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting
Hanny Al-Samkari
Medical oncologist discussing ASH papers
Massachusetts General Hospital
Episode: Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr. Hanny Al-Samkari
Medical oncologist discussing ASH 2025 ITP papers
Massachusetts General Hospital, Boston
Episode: Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr. Sagar Lonial
A leading oncologist specializing in multiple myeloma
Winship Cancer Institute of Emory University
Episode: Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review
Dr. Matthew Lunning
Medical Oncologist from the University of Nebraska, Fred and Pamela Buffett Cancer Center
University of Nebraska, Fred and Pamela Buffett Cancer Center
Episode: Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Dr. Eunice Wang
Medical Oncologist at Roswell Park Comprehensive Cancer Center
Roswell Park Comprehensive Cancer Center
Episode: Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA
Gus Issa
An expert from the University of Texas MD Anderson Cancer Center
University of Texas MD Anderson Cancer Center
Episode: Acute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin Inhibitors
Dr. Neel Pasricha
Ophthalmologist and Cornea Specialist at the University of California, San Francisco
University of California, San Francisco
Episode: Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

Host

Dr. Neil Love
Host of the program and long-time CME-focused interviewer; frequently presents expert insights from hematology/oncology meetings.

Reviews

4.7 out of 5 stars from 129 ratings
  • A debt of gratitude that cannot be repaid

    That is how I feel about Dr Neil Love and his tireless work in continuing medical education for everyone in the medical field. These podcasts and discussions contained are informative, thought provoking and provide and excellent in depth but quick update in the rapidly ever-changing field of Hematology-Oncology.

    Apple Podcasts
    5
    Bongir
    United States3 years ago
  • Excellent content

    Always informative, always applies to those of us on the ground making difficult daily decisions on management in the community. Often with limited resources.

    Apple Podcasts
    5
    ZomBucker
    United States4 years ago
  • Excellent up to date reviews.

    I

    Apple Podcasts
    5
    IanMack5000
    United States15 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Clinically rich, current updates that translate to real-world decisions.
Strong expert perspectives and practical tips for patient care.
Keeps me informed on ASH data in a concise format, great for busy practitioners.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#143
China/Science
Apple Podcasts
#186
Singapore/Science
Apple Podcasts
#227
Brazil/Science
Apple Podcasts
#241
Austria/Science

Talking Points

Recent interactions between the hosts and their guests.

Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
Q: How does enalumab compare to rituximab mechanistically and in outcomes?
Enalumab is disease-modifying by targeting B-cell activating factor signaling, whereas rituximab depletes B cells and can increase BAF; in some short-term outcomes Rituximab and enalumab may appear similar, but mechanisms and longer-term effects differ with enalumab potentially offering more durable disease modification.
Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
Q: Would you personally use this agent right away in your practice if it were available?
If available, I would certainly consider using it in similar patients as those enrolled in VEHIT-2, especially those who have relapsed after steroids, and I would explore its use in patients with multiple prior therapies.
Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
Q: So long as you don't have HIV-induced ITP or CLL-induced ITP, you can enroll on the VEHIT-1 study.
Yes, VEHIT-1 is designed for most primary ITP patients meeting those exclusions, aiming to answer whether early intervention can sustain platelet counts and reduce the need for steroids.
CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah
Q: What clinical scenarios are most promising for integrating subcutaneous administration or frontline use?
Subcutaneous administration may enable outpatient delivery with favorable PK, enabling integration into frontline MRD-guided strategies, while ongoing trials seek to replace or reduce heavy chemotherapy in selected patients, particularly older or high-risk groups.
CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah
Q: What was the thinking behind developing additional CD19-directed agents beyond Blenatumumab?
The goal was to build on Blenatumumab's success while addressing limitations such as toxicity, durability of response, and CNS/extramedullary disease; newer agents use strategies like Fc silencing, altered CD3 affinity, or alternative CD19 binders to optimize safety and efficacy.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Hematologic Oncology Update

What is Hematologic Oncology Update about and what kind of topics does it cover?

High-level interviews with leading hematology/oncology experts cover the latest advances in hematologic cancers, with a strong emphasis on data from major conferences and evolving treatment paradigms. Conversations frequently explore immunotherapy, cellular therapies, targeted agents, and real-world applicability across diseases like ALL, CLL, ITP, and multiple myeloma, often tying trial results to frontline and relapse management. Noteworthy is a consistent focus on balancing efficacy with tolerability, MRD-driven decision making, and practical guidance for clinicians navigating rapidly changing treatment landscapes.

Where can I find podcast stats for Hematologic Oncology Update?

Rephonic provides a wide range of podcast stats for Hematologic Oncology Update. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Hematologic Oncology Update and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Hematologic Oncology Update get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Hematologic Oncology Update, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Hematologic Oncology Update?

Rephonic provides comprehensive predictive audience data for Hematologic Oncology Update, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Hematologic Oncology Update have?

To see how many followers or subscribers Hematologic Oncology Update has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Hematologic Oncology Update?

These podcasts share a similar audience with Hematologic Oncology Update:

1. Blood Cancer Talks
2. Two Onc Docs
3. Blood Podcast
4. WolverHeme Happy Hour
5. Oncology Today with Dr Neil Love

How many episodes of Hematologic Oncology Update are there?

Hematologic Oncology Update launched 18 years ago and published 545 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Hematologic Oncology Update?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Hematologic Oncology Update?

Rephonic pulls ratings and reviews for Hematologic Oncology Update from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Hematologic Oncology Update?

Rephonic provides full transcripts for episodes of Hematologic Oncology Update. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Hematologic Oncology Update?

Recent guests on Hematologic Oncology Update include:

1. Bijal Shah
2. Constantine Tam
3. Hanny Al-Samkari
4. Dr. Hanny Al-Samkari
5. Dr. Sagar Lonial
6. Dr. Matthew Lunning
7. Dr. Eunice Wang
8. Gus Issa

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days